Baader Bank Aktiengesellschaft’s Matinas BioPharma MTNB Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-318	Closed	-$2.05K	–	509
2024 Q2	$2.05K	Buy	+318	New	+$2.88K	﹤0.01%	420
2023 Q4	–	Sell	-671	Closed	-$3.77K	–	371
2023 Q3	$3.77K	Buy	671 +420	+167%	+$5.16K	﹤0.01%	304
2023 Q2	$3.5K	Buy	+251	New	+$5.85K	﹤0.01%	391

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Baader Bank Aktiengesellschaft's MTNB Position: Q3 2024 in Review

Baader Bank Aktiengesellschaft sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 318 shares — an estimated $2.05K sold.

Baader Bank Aktiengesellschaft first reported a position in MTNB in Q2 2023 and held it in 3 quarters. The position peaked at $3.77K in Q3 2023. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

Baader Bank Aktiengesellschaft reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
Baader Bank Aktiengesellschaft sold 318 Matinas BioPharma shares in Q3 2024, an estimated $2.05K.
Baader Bank Aktiengesellschaft first reported a position in Matinas BioPharma in Q2 2023 and held it in 3 quarters.
Baader Bank Aktiengesellschaft's Matinas BioPharma position peaked at $3.77K in Q3 2023.
18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q3 2024, filed 29 Oct 2024.